The FDA has approved Foundayo, an oral GLP-1 medication, as an alternative to existing weight loss treatments such as Wegovy and possibly Ozempic. Foundayo, developed by Eli Lilly, is expected to compete with other obesity treatments in the market. The approval of Foundayo may be subject to further safety data collection, as the FDA is seeking more information on its safety.